Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contemporary Immunosuppression in Simultaneous Heart-Kidney Transplantation: A United Network for Organ-Sharing Database Analysis.

Pharmacotherapy·2026
Same author

Short-Term Care Burden After Left Ventricular Assist Device Implantation and Heart Transplant in the United States.

Journal of the American Heart Association·2026
Same author

Harnessing the Power of Artificial Intelligence to Enhance Drug Therapy Research.

Pharmacotherapy·2026
Same author

Impact of Selective Serotonin Reuptake Inhibitors on Bleeding Rates in HeartMate 3 Left Ventricular Assist Device Patients Not Taking Aspirin.

Artificial organs·2025
Same author

Utilizing Machine Learning to Identify Predictors of Corticosteroid Discontinuation 1-Year After Adult Heart Transplant.

Pharmacotherapy·2025
Same author

Re: Optimizing the handling of missing data in the UNOS database.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2025
Same journal

Recent and anticipated novel drug approvals (Q2 2026 through Q1 2027).

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Optimizing transitions from direct factor Xa inhibitors to unfractionated heparin therapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Impact of pharmacist involvement on hospital sepsis response teams.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Attributes of centralized health-system specialty pharmacy clinics: A scoping review using the Donabedian model.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Zoliflodacin: A novel single-dose oral antibiotic for uncomplicated urogenital gonorrhea.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Implementation of a paid apprenticeship-model pharmacy technician training program.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Probable enoxaparin-induced hepatotoxicity.

Erica L Baker1, Theodore Loewenthal, Edward Salerno

  • 1Evidence-Based Practice Center, Hartford Hospital, Hartford, CT, USA. wbaker01@harthosp.org

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|March 21, 2009
PubMed
Summary
This summary is machine-generated.

This case report details a probable instance of enoxaparin-induced liver injury. A patient experienced rapid and significant elevation of liver enzymes after starting enoxaparin therapy.

Related Experiment Videos

Last Updated: Jun 24, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Area of Science:

  • Hepatology
  • Pharmacology
  • Internal Medicine

Background:

  • Pulmonary embolism (PE) is a serious condition requiring anticoagulation.
  • Enoxaparin is a common low-molecular-weight heparin used for anticoagulation.
  • Drug-induced liver injury (DILI) is a significant concern in clinical practice.

Observation:

  • A 29-year-old woman presented with symptoms suggestive of PE.
  • Computed tomography angiography confirmed multiple bilateral pulmonary emboli.
  • Anticoagulant therapy was initiated with enoxaparin and warfarin.

Findings:

  • The patient developed nausea and vomiting on the second day of enoxaparin therapy.
  • Laboratory tests revealed elevated alanine transaminase (ALT) and aspartate transaminase (AST) levels.
  • Hepatitis A, B, and C were ruled out, and other organ abnormalities were absent.
  • Enoxaparin was discontinued, leading to the resolution of liver enzyme elevations.
  • The Naranjo scale indicated probable enoxaparin-induced hepatotoxicity.

Implications:

  • This case highlights the potential for enoxaparin to cause rapid and severe hepatotoxicity.
  • Clinicians should monitor liver function in patients receiving enoxaparin, especially with rapid or high-magnitude enzyme elevations.
  • Prompt recognition and discontinuation of the offending agent are crucial for managing drug-induced liver injury.